HAYWARD, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Solexa, Inc. (NASDAQ:SLXA) yesterday announced that its scientists, in collaboration with researchers at the Wellcome Trust Sanger Institute, have sequenced a human X-chromosome. The initial results from this project, which were presented yesterday at the Genomes, Medicine and the Environment Conference in Hilton Head, South Carolina, demonstrate that the Solexa Genome Analysis System is achieving the data quality, read length and coverage uniformity required for discovering and characterizing human sequence variation at the genome-wide level. Solexa expects to be the first to deliver whole human genome sequencing at $100,000 per genome.
